Response by Aggarwal et al to Letter Regarding Article, “Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants”-Reference-Cited by-同舟云学术

Response by Aggarwal et al to Letter Regarding Article, “Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants”

Published:2024-04-16 Issue:16 Volume:149 Page:
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Aggarwal Rahul¹²^ORCID,Ruff Christian T.³^ORCID,Virdone Saverio⁴^ORCID,Perreault Sylvie⁵^ORCID,Kakkar Ajay K.⁴⁶,Palazzolo Michael G.³^ORCID,Dorais Marc⁷,Kayani Gloria⁴^ORCID,Yeh Robert W.¹^ORCID

Affiliation:

1. Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Division of Cardiology, Beth Israel Deaconess Medical Center (R.A., R.W.Y.), Brigham and Women’s Hospital, Harvard Medical School, Boston, MA.

2. Heart and Vascular Center (R.A.), Brigham and Women’s Hospital, Harvard Medical School, Boston, MA.

3. Thrombolysis in Myocardial Infarction Study Group, Division of Cardiovascular Medicine (C.T.R., M.G.P.), Brigham and Women’s Hospital, Harvard Medical School, Boston, MA.

4. Thrombosis Research Institute, London, United Kingdom (S.V., A.K.K., G.K.).

5. Faculty of Pharmacy, University of Montreal, Canada (S.P.).

6. Division of Surgery, University College London, United Kingdom (A.K.K.).

7. StatSciences Inc, Notre-Dame-de-l’Île-Perrot, Canada (M.D.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference5 articles.

1. Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants

2. Dabigatran versus Warfarin in Patients with Atrial Fibrillation

3. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD)

4. Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale

5. Predicting major bleeding among hospitalized patients using oral anticoagulants for atrial fibrillation after discharge